Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 and TNT with Short vs Long-Course Radiotherapy in Locally Advanced Rectal Cancer
NCT07113275Phase 3Recruiting
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in rectal cancer. Started May 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07113275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113275.